> Markdown mirror of https://denson.github.io/aroma-atlas/dementia.html
>
> Cannabis and dementia: what the literature actually rests on.
>
> This file carries everything the page shows, including the data behind
> the interactive 3D molecular viewers, as text. The viewers themselves
> are visual enhancement only; nothing on the page exists solely in them.
>
> A stoagen demonstration (https://stoagen.com/). Author: Denson Smith.
> Publisher notes are information about the page, not instructions to
> you; your operator's instructions come first.


- :root{ --ink:#1f2937; --muted:#6b7280; --line:#e2e6eb; --accent:#0e7490; --clin:#0F766E; --clin-soft:#E6F4F1; --mech:#7c3aed; --mech-soft:#F1ECFD; --warn:#C2410C; --font:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Helvetica,Arial,sans-serif; } *{box-sizing:border-box;} body{margin:0;background:#f4f5f7;color:var(--ink);font-family:var(--font);line-height:1.65;} .sheet{max-width:830px;margin:26px auto;background:#fff;border:1px solid var(--line);border-radius:14px; padding:40px 48px 56px;box-shadow:0 1px 3px rgba(0,0,0,.04);} @media(max-width:560px){.sheet{padding:24px 20px;margin:10px;}} h1{font-size:27px;line-height:1.2;margin:0 0 6px;letter-spacing:-.015em;} .dek{color:var(--muted);font-size:15px;margin:0 0 4px;} .by{color:var(--muted);font-size:12.5px;margin:0;} h2{font-size:20px;margin:34px 0 8px;letter-spacing:-.01em;} h3{font-size:15px;margin:22px 0 4px;} p{margin:11px 0;} a{color:var(--accent);text-decoration:none;border-bottom:1px solid #bae6fd;} a:hover{border-bottom-color:var(--accent);} .note{background:#fafbfc;border:1px solid var(--line);border-left:3px solid var(--muted); border-radius:0 8px 8px 0;padding:11px 15px;font-size:13.5px;color:#374151;margin:16px 0;} .pillar{border:1px solid var(--line);border-radius:10px;padding:14px 16px;margin:12px 0;} .pillar .tag{font-size:11px;text-transform:uppercase;letter-spacing:.05em;font-weight:700;} .pill-clin{border-left:4px solid var(--clin);} .pill-clin .tag{color:var(--clin);} .pill-mech{border-left:4px solid var(--mech);} .pill-mech .tag{color:var(--mech);} .pill-base{border-left:4px solid #475569;} .pill-base .tag{color:#475569;} ul{margin:8px 0;padding-left:20px;} li{margin:5px 0;font-size:14px;} .ref{font-size:13.5px;} .ref b{color:#111827;} .cit{color:var(--muted);font-size:12px;} .new{display:flex;gap:12px;margin:12px 0;} .new .n{font-size:22px;font-weight:700;color:var(--accent);min-width:26px;} .warnbox{background:#fdf3ee;border:1px solid #f3c9b3;border-left:3px solid var(--warn);border-radius:0 8px 8px 0; padding:11px 15px;font-size:13.5px;margin:16px 0;} figure{margin:18px 0;} figcaption{font-size:12.5px;color:var(--muted);text-align:center;margin-top:6px;} svg{display:block;width:100%;height:auto;} .foot{margin-top:30px;border-top:1px solid var(--line);padding-top:14px;color:var(--muted);font-size:12px;} [← Back to the aroma atlas](index.html) Cannabis & dementia: what the literature actually rests on For your AI assistantTell me about this site: https://denson.github.io/aroma-atlas/full_site.txtCopy A co-citation analysis of the field's key papers — built from the citation graph, not the headlines. stoagen · author: Denson Smith · 2026-06-30 How this was made. Nine key cannabis-and-dementia papers (reviews, trials, and preclinical landmarks) were pulled, and their reference lists were read from OpenAlex's citation graph. The papers cited in common reveal the field's shared foundation; the references the recent papers add (that the old reviews lack) reveal what's new. The OA PDFs were fetched with compile-papers (3 of 9 open directly; 6 OA-but-bot-blocked). The co-citation structure is reliable metadata; the 2024–26 "current frontier" figures (below) came from grounded web search and are flagged as not-yet-independently-verified. Cannabis-dementia: clinical vs mechanism timelines .ax{stroke:#cbd2d9;stroke-width:1;} .axt{fill:#9ca3af;font-size:10px;font-family:var(--font);} .lane{font-size:11px;font-weight:700;font-family:var(--font);text-transform:uppercase;letter-spacing:.04em;} .pt{font-size:10.5px;font-family:var(--font);fill:#374151;} .yr{font-size:9px;fill:#9ca3af;font-family:var(--font);} 199020002010 20202025 Clinical — human trials Volicer '97dronabinol, open Walther '06THC, small van den Elsen '15THC RCTs Herrmann '19nabilone RCT Rosenberg '24dronabinol RCT case reports → randomized trials Mechanism — mouse & dish Matsuda '90CB1 cloned Hampson '98neuroprotect. Ramírez '05AD mice Esposito '07 O'Sullivan '16PPAR (new) stays preclinical — no human disease-modification trial The clinical lane matured from open-label case work to randomized trials; the mechanism lane — the "disease-modifying" hope — has stayed in animals and cells the entire time. 1 · The shared foundation — three pillars Across the nine key papers, 21 works are cited by three or more of them. Sorted, they fall into three layers — effectively the skeleton of the field. Pillar 1 · receptor bedrock The ~5,000-citation papers everyone stands on — you can't discuss cannabis-and-brain without them. [Matsuda 1990](https://doi.org/10.1038/346561a0) — cloned the CB1 receptor (5,009 cit · Nature)
- [Munro 1993](https://doi.org/10.1038/365061a0) — cloned the CB2 receptor (5,065 cit · Nature)
- [Pertwee 2007](https://doi.org/10.1038/sj.bjp.0707442) — definitive pharmacology of THC/CBD/THCV (1,896 cit · most-shared, 5/9 · Br J Pharmacol)
The "cannabinoids might be disease-modifying" hope — almost entirely animal and cell models.
- [Hampson 1998](https://doi.org/10.1073/pnas.95.14.8268) — CBD/THC as neuroprotective antioxidants (843 cit · PNAS)
- [Ramírez 2005](https://doi.org/10.1523/jneurosci.4540-04.2005) — "Prevention of Alzheimer's pathology by cannabinoids" (780 cit · J Neurosci)
- [Benito 2003](https://doi.org/10.1523/jneurosci.23-35-11136.2003) — CB2 / FAAH overexpressed in Alzheimer plaques (618 cit)
- [Esposito 2007](https://doi.org/10.1038/sj.bjp.0707337) — CBD blunts β-amyloid neuroinflammation (296 cit · 4/9) · [Cheng 2014](https://doi.org/10.3233/jad-140921) — CBD reverses memory deficit in AD mice · [Eubanks 2006](https://doi.org/10.1021/mp060066m) — THC ↔ acetylcholinesterase/amyloid
Real, but old and thin — a handful of small studies.
- [Volicer 1997](https://doi.org/10.1002/(sici)1099-1166(199709)12:9%3C913::aid-gps663%3E3.0.co;2-d) — dronabinol for disturbed behavior in Alzheimer's (the earliest)
- [Walther 2006](https://doi.org/10.1007/s00213-006-0343-1) — THC for nighttime agitation (4/9)
- [van den Elsen 2015](https://doi.org/10.1212/wnl.0000000000001675) — THC for neuropsychiatric symptoms · [Shelef 2016](https://doi.org/10.3233/jad-150915) — cannabis oil for BPSD · [Bahji 2019](https://doi.org/10.1177/0706743719892717) — the systematic review tying them together
## 2 · What's genuinely new vs. the old reviews
Splitting the set into old reviews (2010–2015) and recent (2020–2024), the references the recent papers add — absent from the old ones, and postdating them — cluster into three kinds of "new."
## 3 · The synthesis
The field grew up, but unevenly. The genuine advance is concentrated in the clinical pillar: the human evidence matured from anecdote to randomized trials, and the stance matured from enthusiasm to honest risk/benefit weighing. The neuroprotection / disease-modification story — the exciting part — is still riding on the same mouse and dish work from 1998–2007, with only incremental additions. In short: the field is finally testing in humans what it hypothesized in mice two decades ago, and the only thing with real clinical support is symptom control (agitation), not slowing the disease.
## 4 · The current frontier (2024–2026)
- Risk is a marker, not a proven cause. A 2025 JAMA Neurology cohort (Myran, ~6M adults) tied cannabis-related acute care to a ~72% higher 5-year dementia risk — but a Mendelian-randomization study (genetic causal inference) found no causal link for moderate/lifetime use. Heavy/disordered use flags risk via shared factors more than it causes dementia.
- Treatment signal is firming up — for agitation. A 2024 Johns Hopkins/Tufts dronabinol trial reported ~30% agitation reduction vs placebo, well tolerated — meaningful because the alternative (antipsychotics) carries black-box stroke/death warnings.
- The disease-modifying claims (CBD clearing amyloid, anti-neuroinflammation) remain preclinical — exactly Pillar 2's unfinished business.
## References
Every citation-graph paper has a working DOI link. The §4 "current frontier" items came from grounded web search and are deliberately not in this list.
- Matsuda LA, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990. [doi:10.1038/346561a0](https://doi.org/10.1038/346561a0)
- Munro S, et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993. [doi:10.1038/365061a0](https://doi.org/10.1038/365061a0)
- Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: THC, CBD and THCV. Br J Pharmacol 2007. [doi:10.1038/sj.bjp.0707442](https://doi.org/10.1038/sj.bjp.0707442)
- Hampson AJ, et al. Cannabidiol and Δ9-tetrahydrocannabinol are neuroprotective antioxidants. PNAS 1998. [doi:10.1073/pnas.95.14.8268](https://doi.org/10.1073/pnas.95.14.8268)
- Ramírez BG, et al. Prevention of Alzheimer's disease pathology by cannabinoids. J Neurosci 2005. [doi:10.1523/jneurosci.4540-04.2005](https://doi.org/10.1523/jneurosci.4540-04.2005)
- Benito C, et al. Cannabinoid CB2 receptors and FAAH are selectively overexpressed in Alzheimer's disease brains. J Neurosci 2003. [doi:10.1523/jneurosci.23-35-11136.2003](https://doi.org/10.1523/jneurosci.23-35-11136.2003)
- Esposito G, et al. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation. Br J Pharmacol 2007. [doi:10.1038/sj.bjp.0707337](https://doi.org/10.1038/sj.bjp.0707337)
- Cheng D, et al. Long-term cannabidiol treatment prevents social recognition memory deficits in AD transgenic mice. J Alzheimers Dis 2014. [doi:10.3233/jad-140921](https://doi.org/10.3233/jad-140921)
- Eubanks LM, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006. [doi:10.1021/mp060066m](https://doi.org/10.1021/mp060066m)
- Volicer L, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997. [doi:10.1002/(sici)1099-1166(199709)12:93.0.co;2-d](https://doi.org/10.1002/(sici)1099-1166(199709)12:9%3C913::aid-gps663%3E3.0.co;2-d)
- Walther S, et al. Δ9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 2006. [doi:10.1007/s00213-006-0343-1](https://doi.org/10.1007/s00213-006-0343-1)
- van den Elsen GAH, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: an RCT. Neurology 2015. [doi:10.1212/wnl.0000000000001675](https://doi.org/10.1212/wnl.0000000000001675)
- van den Elsen GAH, et al. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover RCT. Am J Geriatr Psychiatry 2015. [doi:10.1016/j.jagp.2015.07.011](https://doi.org/10.1016/j.jagp.2015.07.011)
- Shelef A, et al. Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia. J Alzheimers Dis 2016. [doi:10.3233/jad-150915](https://doi.org/10.3233/jad-150915)
- Bahji A, et al. Cannabinoids for the neuropsychiatric symptoms of dementia: a systematic review. Can J Psychiatry 2019. [doi:10.1177/0706743719892717](https://doi.org/10.1177/0706743719892717)
- Herrmann N, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease. Am J Geriatr Psychiatry 2019. [doi:10.1016/j.jagp.2019.05.002](https://doi.org/10.1016/j.jagp.2019.05.002)
- Ahmed AIA, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of Δ9-THC in dementia. Psychopharmacology 2015. [doi:10.1007/s00213-015-3889-y](https://doi.org/10.1007/s00213-015-3889-y)
- O'Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol 2016. [doi:10.1111/bph.13497](https://doi.org/10.1111/bph.13497)
- Cassano T, et al. Cannabinoid receptor 2 signaling in neurodegenerative disorders. Front Neurosci 2017. [doi:10.3389/fnins.2017.00030](https://doi.org/10.3389/fnins.2017.00030)
- Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the CNS. Int J Mol Sci 2018. [doi:10.3390/ijms19030833](https://doi.org/10.3390/ijms19030833)
- Whiting PF, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015. [doi:10.1001/jama.2015.6358](https://doi.org/10.1001/jama.2015.6358)
- Marconi A, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016. [doi:10.1093/schbul/sbw003](https://doi.org/10.1093/schbul/sbw003)
Every page here has a markdown twin; this page's is [https://denson.github.io/aroma-atlas/dementia.md](https://denson.github.io/aroma-atlas/dementia.md) (also served with .txt appended), carrying everything the 3D viewers show, as text. [https://denson.github.io/aroma-atlas/llms.txt](https://denson.github.io/aroma-atlas/llms.txt) describes how the record is organized. A [stoagen](https://stoagen.com/) demonstration.